Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Phase 2

Completed

Conditions: Healthy Volunteers Diabetes Mellitus, Type 2
Healthy Volunteers Overweight
Healthy Volunteers Obesity

Interventions: Drug: Semaglutide (administered by DV3396 pen)
Drug: Semaglutide (administered by PDS290 pen)

First Posted Date: 2019-07-05

Last Posted Date: 2020-08-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 103

Registration Number: NCT04007107

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Placebo (semaglutide)

First Posted Date: 2019-06-18

Last Posted Date: 2023-02-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 961

Registration Number: NCT03989232

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zhytomyr, Ukraine

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Phase 2

Completed

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2019-06-17

Last Posted Date: 2024-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 71

Registration Number: NCT03987451

Locations: 🇺🇸
Texas Clinical Research Institute, LLC, Arlington, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Miami/Schiff Center for Liver Diseases, Miami, Florida, United States

and more 35 locations

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart

First Posted Date: 2019-06-17

Last Posted Date: 2024-06-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT03987802

Locations: 🇮🇳
Max Super Speciality Hospital, Saket, New Delhi, Delhi, India
🇮🇳
Vijayratna Diagnostic & Scientific Obesity Clinic, Ahmedabad, Gujarat, India
🇮🇳
Life Care Clinic & Research Centre, Bangalore, Karnataka, India

and more 23 locations

Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Conditions: Growth Hormone Deficiency in Children
Born Small for Gestational Age

Interventions: Drug: Norditropin® FlexPro®

First Posted Date: 2019-06-03

Last Posted Date: 2024-08-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 750

Registration Number: NCT03972345

Locations: 🇩🇪
Universitätsklinikum Ulm für Kinder- und Jugendmedizin, Ulm, Germany

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Phase 1

Completed

Conditions: Healthy Volunteers
Diabetes Mellitus, Type 1

Interventions: Drug: NNC0268-0965
Drug: Placebo
Drug: insulin glargine

First Posted Date: 2019-05-28

Last Posted Date: 2021-01-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 78

Registration Number: NCT03965013

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin detemir

First Posted Date: 2019-05-23

Last Posted Date: 2019-07-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 12847

Registration Number: NCT03960814

Locations: 🇩🇰
Novo Nordisk Investigational Site, Bagsværd, Denmark

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Insulin icodec

First Posted Date: 2019-05-15

Last Posted Date: 2021-04-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 205

Registration Number: NCT03951805

Locations: 🇪🇸
Novo Nordisk Investigational Site, Vic (Barcelona), Spain

A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: insulin icodec
Drug: Insulin glargine

First Posted Date: 2019-05-10

Last Posted Date: 2023-09-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT03945656

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide

First Posted Date: 2019-04-29

Last Posted Date: 2023-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 218

Registration Number: NCT03929679

Locations: 🇳🇱
Novo Nordisk Investigational Site, Zwijndrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy